- Respiri (RSH) has received United States Food and Drug Administration (FDA) clearance for its wheezing aid, Wheezo
- Wheezo monitors wheezing to manage and improve asthma
- The technology can also share data with caregivers, physicians and other health care professionals
- With the green tick from the FDA, the company can now market and sell the technology in the United States
- Asthma is a significant problem in the U.S., with around 8 per cent of the population and 7.5 per cent of children living with the disease
- On the market this afternoon, Respiri is in the grey and trading at 17 cents per share
Respiri: Receives FDA tick for Wheezo
